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Arabinoxylans, inulin and Lactobacillus reuteri 1063 repress
the adherent-invasive Escherichia coli from mucus in a
mucosa-comprising gut model
Pieter Van den Abbeele1,3, Massimo Marzorati1,3, Melanie Derde1, Rosemarie De Weirdt1, Vermeiren Joan1, Sam Possemiers1,2
and Tom Van de Wiele1
The microbiota that colonises the intestinal mucus may particularly affect human health given its proximity to the epithelium. For
instance, the presence of the adherent-invasive Escherichia coli (AIEC) in this mucosal microbiota has been correlated with Crohn’s
disease. Using short-term screening assays and a novel long-term dynamic gut model, which comprises a simulated mucosal
environment (M-SHIME), we investigated how (potential) pro- and prebiotics may repress colonisation of AIEC from mucus. Despite
that during the short-term screening assays, some of the investigated Lactobacillus strains adhered strongly to mucins, none of
them competed with AIEC for mucin-adhesion. In contrast, AIEC survival and growth during co-culture batch incubations was
decreased by Lactobacillus rhamnosus GG and L. reuteri 1063, which correlated with (undissociated) lactic acid and reuterin levels.
Regarding the prebiotics, long-chain arabinoxylans (LC-AX) lowered the initial mucin-adhesion of AIEC, while both inulin (IN) and
galacto-oligosaccharides (GOS) limited AIEC survival and growth during batch incubations. L. reuteri 1063, LC-AX and IN were thus
retained for a long-term study with the M-SHIME. All treatments repressed AIEC from mucus without affecting AIEC numbers in the
luminal content. As a possible explanation, L. reuteri 1063 treatment increased lactobacilli levels in mucus, while LC-AX and IN
additionally increased mucosal biﬁdobacteria levels, thus leading to antimicrobial effects against AIEC in mucus. Overall, this study
shows that pro- and prebiotics can beneﬁcially modulate the in vitro mucosal microbiota, thus limiting occurrence of opportunistic
pathogens among those mucosal microbes which may directly interact with the host given their proximity to the epithelium.
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INTRODUCTION
Along the intestinal tract, the host epithelium is covered by a
protective mucus layer that contains speciﬁc microbes1 and
several factors contribute to a distinct microbiota in the luminal
content versus the mucus layer.2 First, the host selects microbes
that colonise mucus by producing defence molecules such as
antimicrobial peptides (AMPs) and IgA.3 Selection also occurs
through oxygen diffusion from the blood towards the gut,
resulting in an oxygen gradient along the mucus. The unique
mucosal microbiota composition is further determined by
bacterial factors such as mucus adhesion4 and mucin
degradation.5 The resulting mucosal microbiota as such possesses
a colonisation resistance against opportunistic pathogens. This
includes local excretion of antimicrobial compounds,6 stimulation
of the host immune system,7 production of metabolic compounds
that lower the pH8 and competition with pathogens for nutrients9
and adhesion sites.10
A disruption of the mucosal microbial community may have
adverse implications for human health. Besides an altered
interaction with the immune system, a disrupted mucosal
microbiota may result in increased colonisation by (potential)
pathogens correlated with infectious or chronic gastrointestinal
diseases. As an example, the mucosal microbiota of Crohn’s
disease (CD) patients is characterised by the dominance of
potentially harmful microbes, in particular Escherichia coli, over
beneﬁcial microbes such as Faecalibacterium prausnitzii and
Roseburia sp.11,12 In fact, the adherent-invasive Escherichia coli
(AIEC), a strain proposed as a causative agent of CD, can strongly
adhere to and invade intestinal epithelial cells in patients by
means of a protease called Vat-AIEC.13,14
While in vivo studies are restricted to end-point measurements
regarding mucosal microbes,1 in vitro assays allow to study
mechanisms of microbial adhesion. These assays include adhesion
experiments to mucus,15 mucins,16 colonic tissue17 and cell lines.18
Because these models only provide short-term information and
ignore the interaction between luminal and mucosal microbes,
we modiﬁed a dynamic in vitro model for the luminal microbiota
by incorporating mucin-covered microcosms (M-SHIME). The
validation of this M-SHIME model followed from the more
representative colonisation of Lactobacillus sp.19 Furthermore,
high-resolution phylogenetic characterisation showed that the
simulated mucosal microbiota was, in correspondence with in vivo
studies, enriched with Firmicutes sp. belonging to Clostridium
clusters IV and XIVa.20 The same study showed that the in vitro
mucosal environment is necessary to avoid wash-out of relevant
surface-attached microbes.
As reinforcing the mucosal microbiota may be a strategy to
restore the host-microbe interaction when disturbed, the
objective of this study was to evaluate the efﬁcacy of several
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strategies to enhance the mucosal microbiota in repressing
opportunistic pathogens from the mucosal environment. To
demonstrate the proof-of-principle, we used AIEC as a model
opportunistic pathogen, as AIEC is known to strongly adhere to
mucus in CD patients, while the ampicillin/erythromycin-resistant
reference strain LF8221 enables straightforward detection of viable
AIEC cells in the background of a mixed intestinal microbiota.
Using short-term screening assays, we evaluated how selected
pre- and probiotics may inhibit the initial adhesion of AIEC to
intestinal mucins, as well as the survival/growth of AIEC.
A selection of treatments was then applied in the M-SHIME to
investigate whether AIEC was repressed in a simulated mucosal
environment during a long-term interaction with the resident
luminal and mucosal microbiota of a single donor.
RESULTS
Short-term mucin-adhesion experiments
As inhibition of AIEC adhesion by Lactobacillus strains may depend
on competition for mucin-binding sites, the intrinsic adhesion
capacity of the probiotic strains was evaluated in a ﬁrst
experiment. This showed that the strains signiﬁcantly differed in
their intrinsic adhesion capacity (Figure 1a). While the adhesion
capacity of Lactobacillus rhamnosus GG was strong and compar-
able to that of AIEC (~20%), Pediococcus acidilactici LB1 adhered
poorly (~3%). Adhesion of L. mucosae LB2, L. reuteri 1063 and
L. acidophilus NCFM was intermediate (~10%). However, none of
the tested Lactobacillus strains lowered adhesion of AIEC in
competition experiments, as compared with the AIEC control
without probiotics (Figure 1b).
In contrast, two prebiotic compounds interfered with the
initial adhesion of AIEC to mucins (Figure 1c). While fructo-
oligosaccharides (FOS) and inulin (IN) had no inﬂuence, long-chain
arabinoxylan (LC-AX) signiﬁcantly inhibited adhesion of AIEC
(P= 0.008). Finally, in presence of galacto-oligosaccharides (GOS),
the adhesion of AIEC was signiﬁcantly higher (P= 0.009).
Short-term survival/growth inhibition assay
On inoculation of AIEC in the nutritional medium, a good growth
was monitored with a factor 60 increase in the control after 24 h.
All strains tested, except L. mucosae LB2, inhibited AIEC
survival/growth (Table 1). AIEC numbers after 24-h incubation
were signiﬁcantly lower—as compared with the control—in the
presence of P. acidilactici LB1, L. acidophilus NCFM, L. rhamnosus
GG and L. reuteri 1063. For these last two strains, a complete
eradication of AIEC below detection limit was observed. As AIEC is
able to produce both acetate and ammonium, these metabolites
are potential markers for AIEC growth, even if it has to be taken
into account that these metabolites can also remain high due to
growth of other species. Acetate levels correlated with AIEC
growth/survival, with the exception of the co-culture with L. reuteri
1063, in which acetate levels remained high despite the fact that
AIEC was eradicated. Ammonium levels only decreased for the
treatments that eradicated AIEC below detection limit, i.e.,
L. reuteri 1063 and L. rhamnosus GG. To provide an explanation
for the observed antimicrobial effects, the pH decrease and
concentrations of D/L-lactic acid (and its antimicrobial fraction, i.e.,
undissociated lactic acid), 3-HPA and 1,3-PDO (markers for
reuterin) were determined. It followed that a decrease in AIEC
numbers corresponded with lower pH and increased levels
of undissociated lactic acid. The strong antimicrobial effect of
L. reuteri 1063 was plausibly due to the combined action of
undissociated L-lactic acid and reuterin (approximate increase of
3-HPA and 1,3-PDO), while in the case of L. rhamnosus GG it was
related to high levels of undissociated L-lactic acid.
The indirect antimicrobial effect of oligo- and polysaccharides
has been evaluated in relation to the production of metabolites
resulting from microbial catabolism. In this respect, the nutritional
medium was inoculated with AIEC and also with 5 × 106 c.f.u.
per ml of an ascending colon suspension from a SHIME system
(control B). It was found that this mixed microbiota already
exerted a vast inhibitory effect on AIEC growth (approximately
only factor 0.27 increase after 24 h in control B in contrast
to control A without mixed microbiota, which showed a
57.2 ± 19.7-fold increase) (Table 2). Both GOS and IN further
enhanced the inhibitory effect of this mixed microbiota against
AIEC, while LC-AX did not affect AIEC. For GOS, the decrease in
AIEC levels coincided with a lower pH and more undissociated
lactic acid, while for IN higher levels of 1,3-PDO and thus
potentially more reuterin were observed as opposed to the other
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Figure 1. (a) Mean intrinsic mucin-adhesion capacity of AIEC (± s.d.)
(n= 16) and several Lactobacillus strains (n= 4), expressed as a ratio
of the amounts of adhered bacteria compared with initially added
bacteria (108 cells per ml). (b) Adhesion of AIEC in the presence of
several Lactobacillus strains, as a ratio compared with the control
where only AIEC was added (n= 4). (c) Adhesion of AIEC in the
presence of several prebiotic compounds (LC-AX; n= 7, FOS; n= 4,
IN; n= 4 and GOS; n= 4), as a ratio compared with the control where
only AIEC was added (n= 11). Values indicated with a different
superscript are signiﬁcantly different (P⩽0.05; a, b or c).
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prebiotics. Despite elevated levels of undissociated lactic acid, FOS
inhibited the growth of AIEC less than what is seen for control B.
Given the metabolic activity of the mixed microbiota, acetate and
ammonium were no optimal markers for AIEC growth. Together
with propionate, butyrate and the total SCFA levels, they rather
indicated the growth of the mixed intestinal microbiota.
Long-term M-SHIME study
Based on initial screenings, three treatments were applied in a
follow-up M-SHIME experiment (i.e., L. reuteri 1063, LC-AX and IN)
with the aim of understanding whether AIEC is repressed from a
simulated mucosal environment during a long-term interaction
with the resident luminal and mucosal microbiota.
The AIEC numbers (c.f.u. per ml) in the luminal environment
were similar between the different ascending colon units of the
M-SHIME, but tended to be lower in that of the L-SHIME, which
lacks a mucosal environment (Figure 2a). In contrast, AIEC counts
within the mucosal environment were at least 1-log unit lower as
compared with the control as a result of the treatments in the
M-SHIME (Figure 2b). On inoculation of AIEC (on day 22, 23, 24 and
25), LC-AX immediately decreased AIEC in the mucus (day 24).
During further treatment, supplementation of L. reuteri 1063,
LC-AX and IN was similarly effective in lowering AIEC numbers in
Table 1. The increase in AIEC numbers after 24-h incubation with different Lactobacillus sp., as a ratio compared with the initial AIEC count
(5 × 106 c.f.u. per ml) (n= 3)
Control LGG L. reuteri 1063 L. mucosae LB2 L. acidophilus NCFM P. acidilactici LB1
AIEC (fold increase) 57.2± 19.7a 0.0±0.0b 0.0± 0.0b 44.3± 7.4a 1.3±1.0c 8.8±6.4d
Potential markers for AIEC growth
Acetate (mM) 4.95± 0.67a 0.49±0.86b 4.49± 0.32a 5.01± 0.21a 2.99±0.71c 3.24±0.72c
Ammonium (mM) 4.52± 0.36a 0.08±0.38b 2.85±0.53c 6.62± 0.21d 4.37± 0.65a 4.64± 0.06a
Antimicrobial factors
D-lactic acid (mM) 0.66± 0.17ab 0.31± 0.04a 0.72± 0.18bc 1.49±0.14d 1.23± 0.31cd 1.78±0.32d
L-lactic acid (mM) 0.54± 0.14a 4.98±0.17b 1.36±0.12c 1.66±0.17c 2.97±0.44d 3.11±0.35d
Acidity (pH) 5.27± 0.02a 4.20±0.03b 4.52±0.01c 5.34 ± 0.01a 4.95±0.21d 4.66±0.10e
Undissociated lactic acid (%) 3.7± 0.1a 31.5±1.3b 18.0±0.3c 3.2± 0.1a 7.9±3.4d 13.7± 2.8e
Undissociated lactic acid (mM) 0.04± 0.01a 1.67±0.06b 0.37±0.04c 0.10±0.00d 0.35±0.05c 0.67±0.08e
3-HPA (mM) BDL BDL 3.44±0.25 BDL BDL BDL
1,3-PDO (mM) BDL BDL 9.46±0.26 BDL BDL BDL
Abbreviations: AIEC, adherent-invasive Escherichia coli; BDL, below detection limit.
Possible antimicrobial factors include D- and L-lactic acid (mM), acidity (pH), corresponding undissociated lactic acid (% and mM) and two markers for reuterin
production (3-HPA (mM), 1,3-PDO (mM)). Acetate (mM) and ammonium (mM) are potential markers for AIEC growth. For optimal visualisation, values that
indicate antimicrobial effects against AIEC are in bold, while different superscripts indicate signiﬁcant differences (a, b, c, d or e). BDL, undissociated lactic acid
(%)= 1/[1+10^(pH −pKa)] × 100%.
Table 2. The increase in AIEC numbers after 24-h incubation in nutritional medium without (control A) or with addition of an equal amount of a
mixed SHIME-derived microbiota (control B) treated with prebiotic compounds (LC-AX, FOS, IN and GOS), expressed as a ratio compared with the
initial AIEC count (5 × 106 c.f.u. per ml) (n= 5)
Control A Control B LC-AX IN FOS GOS
AIEC (fold increase) 57.2± 19.7a 0.27±0.05bc 0.44± 0.25bd 0.09± 0.08c 0.60± 0.22d 0.10± 0.05c
Markers for growth of AIEC and/or mixed microbiota
Acetate (mM) 4.95± 0.67a 16.42± 0.91bc 17.67± 1.35cd 15.06± 1.55b 17.31± 0.54d 24.87± 0.32e
Ammonium (mM) 4.52± 0.36a 7.75± 0.44b 6.88±0.40c 7.72± 0.76b 6.55± 0.44c 6.77± 0.20c
Markers for growth of mixed microbiota
Propionate (mM) BDL 4.74± 0.21a 9.98±0.74b 4.60± 0.35a 7.13± 0.15c 6.87± 0.27c
Butyrate (mM) BDL 1.62± 1.22a 0.15± 0.21b 1.30±1.60ab BDL BDL
Total SCFA (mM) 4.95± 0.67a 22.78± 0.89b 27.80± 1.36c 20.95± 0.57d 24.44± 0.66b 31.74± 0.52e
Antimicrobial factors
D-lactic acid (mM) 0.66±0.17ab 0.29± 0.15a 0.60±0.32ab 0.51±0.44ab 0.81±0.18b 0.70±0.14b
L-lactic acid (mM) 0.54± 0.14a 0.30± 0.07a 0.42± 0.13a 0.46± 0.25a 0.70± 0.38a 1.72±0.43b
Acidity (pH) 5.27± 0.02a 4.93± 0.02b 4.85±0.01c 4.95± 0.01b 4.76±0.0d 4.42±0.01d
Undissociated lactic acid (%) 3.7± 0.1a 7.8± 0.3b 9.2±0.1c 7.5± 0.2b 11.2±0.3d 21.5±0.4e
Undissociated lactic acid (mM) 0.04± 0.01a 0.05± 0.02a 0.09± 0.04a 0.07± 0.05a 0.17±0.03b 0.52± 0.08c
3-HPA (mM) BDL 0.56± 0.77 1.57± 3.51 0.56± 1.55 0.28± 0.63 1.12± 0.62
1,3-PDO (mM) BDL 1.83±0.06a 1.54± 0.05b 1.88± 0.75a 0.59± 0.81c 0.61± 0.83bc
Abbreviations: AIEC, adherent-invasive Escherichia coli; BDL, below detection limit; FOS, fructo-oligosaccharides; IN, inulin; LC-AX, long-chain arabinoxylans.
Possible antimicrobial factors include D- and L-lactic acid (mM), acidity (pH), corresponding undissociated lactic acid (% and mM), markers for reuterin
production (3-HPA (mM), 1,3-DPO (mM)), markers for metabolic activity of the mixed microbiota (propionate, butyrate and total SCFA (mM)), and two markers
for growth of both AIEC and the mixed microbiota (acetate (mM) and ammonium (mM)). For optimal visualisation, values that indicate antimicrobial effects
against AIEC are in bold, while different superscripts indicate signiﬁcant differences between different treatments and/or control A and B (a, b, c, d or e). BDL,
undissociated lactic acid (%)= 1/[1+10^(pH −pKa)] × 100%.
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mucus. After the AIEC administration period, the average decrease
of AIEC in the treated mucus (average calculated on the
concentrations measured on day 27, 29 and 31) was 1.43 ± 0.14
log c.f.u. per g mucus for L. reuteri 1063, 0.98 ± 0.36 log c.f.u. per g
mucus for LC-AX and 1.29 ± 0.27 log c.f.u. per g mucus for IN.
As assessed by DGGE, the overall bacterial community
composition rather clustered according to the location (mucus
or lumen) than according to treatment, caused by different
abundances of subdominant microbes (Supplementary Figure 1A),
suggesting only a minor role of abundant gut anaerobes in the
inhibitory effect towards AIEC. As prebiotic compounds are known
to target subdominant bacteria belonging to lactobacilli and
especially biﬁdobacteria,22 the quantities of these groups were
determined in the luminal and mucosal environment (Table 3).
Supplementation of L. reuteri 1063, LC-AX and IN increased
lactobacilli levels in both lumen and mucus. LC-AX and IN also
increased the levels of Biﬁdobacterium spp. in mucus. Furthermore,
LC-AX and IN altered the Biﬁdobacterium composition. While the
control and L. reuteri 1063-treated vessels were dominated by
B. biﬁdum, LC-AX-stimulated B. longum in lumen and mucus, and
B. adolescentis in mucus. IN led also to a delayed stimulation (i.e.,
day 29) of B. adolescentis in mucus and lumen (Supplementary
Figure 1B). In addition, L. reuteri 1063 elevated lactic acid and
reuterin (~1,3-PDO) levels, while LC-AX and IN only increased
reuterin production (~1,3-PDO) (Table 3).
DISCUSSION
In this study, we provide an in vitro proof-of-principle that pre- and
probiotic strategies can beneﬁcially modulate the mucosal
microbiota and decrease the mucosal colonisation of an
opportunistic pathogen (i.e., Escherichia coli AIEC). Because the
mucosal microbes may directly interact with the host, lowering
the abundance of opportunistic pathogens in the mucosal
compartment may be more relevant than lowering their
abundance in the intestinal content. We used the AIEC as a
model opportunistic pathogen because it is known to adhere
strongly to mucus and because its reference strain LF82 can be
easily detected in a mixed microbiota.21 As the ileal microbiota is
difﬁcult to simulate in vitro due to the lack of a representative
inoculum and the difﬁculty of simulating the host factors that
govern ileal composition (e.g., secretion of AMPs, high ﬂow
through), we simulated the ascending colon considering that AIEC
are associated both with ileal and colonic disease phenotypes.14
After short-term screening assays, a selection of pro- and
prebiotics was applied in a dynamic in vitro model (M-SHIME)
that allows to study both the luminal and mucosal intestinal
microbiota.19 This simulated mucosal environment avoids
wash-out of speciﬁc surface-associated microbes.20 As AIEC also
beneﬁts from mucus adhesion to colonise the human intestine,
this novel model allowed studying the colonisation of AIEC in a
more representative manner compared with earlier models.
The initial mucin-adhesion capacity of AIEC was strong and it
was comparable to that of well-known mucus colonisers such as
L. rhamnosus GG23 and L. reuteri 10634 (Figure 1a). The mucin-
adhesion of AIEC was conﬁrmed during the long-term experiment,
where AIEC was an abundant member of the mucosal microbiota,
even 6 days after its last inoculation (day 31; Figure 2b). The ability
of AIEC to colonise the intestinal surface has been attributed to
active motility through ﬂagella which also regulate expression of
type 1 pili.24 For AIEC, mucus colonisation is crucial to adhere to
and invade host cells.13,25
L. reuteri 1063, LC-AX and IN speciﬁcally lowered AIEC numbers
in the simulated mucosal environment of the M-SHIME, while they
did not affect AIEC numbers in the luminal content. As a possible
explanation, supplementation of IN and LC-AX (during 8 days prior
to AIEC inoculation) altered the resident mucosal microbiota,
especially subdominant groups (lactobacilli and biﬁdobacteria).
Not only did LC-AX and IN increase the mucosal counts of
lactobacilli and biﬁdobacteria, they also altered the species
composition of the biﬁdobacteria. As shown by DGGE, initially
the dominant mucosal Biﬁdobacterium species was B. biﬁdum,
IN speciﬁcally stimulated B. adolescentis in mucus and LC-AX
speciﬁcally stimulated both B. longum and B. adolescentis in
mucus. B. longum has been shown to possess a stronger
antimicrobial activity against Escherichia coli compared with
B. biﬁdum.26 Also B. adolescentis was shown to be very effective
in combating Escherichia coli compared with B. biﬁdum27 but also
compared with many other Biﬁdobacterium and Lactobacillus
species.28 While antimicrobial factors are possibly too diluted in
the intestinal content to be effective, the mucosal environment
may allow trapping of antimicrobial factors, thereby repressing
AIEC. Especially the spatial heterogeneity introduced by the
bioﬁlm on top of the mucin layer may result in local accumulation
of e.g., acids produced by lactobacilli or biﬁdobacteria.
Although the short-term screening assays are inevitably
confounded by drawbacks such as pH drops, nutrient limitation
and accumulation of metabolites, they allowed to demonstrate
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Figure 2. The AIEC numbers in the luminal (log c.f.u. per ml
suspension) (a) and mucosal environment (log c.f.u. per g mucin
agar) (b) of ﬁve ascending colon compartments. The ﬁrst unit
consisted of the conventional setup that only contains luminal
microbes (L-SHIME) (1), whereas the other four units were modiﬁed
by incorporating a mucosal compartment (=M-SHIME). The
L-SHIME and the ﬁrst M-SHIME were fed the normal nutritional
SHIME medium (2a), while the other three were treated with
L. reuteri 1063 (2b), LC-AX (2c) and IN (2d), respectively. AIEC was
inoculated on day 22, 23, 24 and 25 at ~ 2.108 c.f.u. per ml. Samples
were collected before renewal of mucus on day 24, 27, 29 and 31.
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that both the conversion of glycerol to reuterin and the
undissociated lactic acid production are processes that exert
distinct antimicrobial effects on AIEC (Tables 1 and 2). As shown
for LGG and GOS, the antimicrobial effect of lactic acid is
dependent on a concomitant pH decrease as this enhances the
portion of undissociated lactic acid. Only undissociated lactic acid
can pass through the cell wall after which it exerts an
antimicrobial effect by releasing protons in the cytoplasm of
AIEC. While the pH was controlled in the intestinal lumen of the
M-SHIME (pH= 5.6–5.9), the mucosal pH may have decreased
below 5.6 resulting in higher mucosal levels of undissociated lactic
acid (41.79%). Further, for L. reuteri 1063 and the mixed intestinal
microbiota, the presence of the glycerol conversion products,
3-HPA and 1,3-PDO, indicated the production of the potent,
broad-spectrum antimicrobial reuterin capable of inhibiting
growth of many other microbial species, including Escherichia
spp.29–32 As glycerol levels are higher in CD patients33 and in the
upper digestive tract, the conversion of glycerol to reuterin may
be particularly relevant for AIEC eradication.
Another mechanism that may result in lower mucosal AIEC
counts is an adhesion inhibition of AIEC to intestinal mucins.
However, among all (potential) pro- and prebiotics tested (even
the strongly adherent probiotics), LC-AX was the only treatment
that lowered the initial AIEC adhesion (Figure 1b,c). Also during
the long-term M-SHIME study, only LC-AX limited the initial
colonisation of the mucosal environment by AIEC (Figure 2b).
These results are concordant with earlier studies showing that this
speciﬁc LC-AX can lower the initial mucin-adhesion of a wide
variety of bacterial groups including coliforms.16 The latter study
demonstrated that the underlying reason may be that LC-AX
increase the viscosity. Further, physical adhesion inhibition may
occur by binding of microbes to ﬁbres instead of surface
receptors.34 LC-AX-type polysaccharides may thus be interesting
compounds to modulate the initial bacterial adhesion to mucins.
Despite the fact that the mucosal environment was partly
(50%) renewed every 2 days, speciﬁc species cross-contaminated
between old and new mucin-microcosms, resulting in a
distinct microbiota in the luminal and mucosal environment
(Supplementary Figure 1). In previous studies with the M-SHIME,
where the mucosal environment was not renewed, even stronger
differences between the mucosal and luminal microbiota were
observed on day 1 (~60% similarity)19 or day 3 after start-up
(only ~ 15% similarity).20
In conclusion, we showed that the M-SHIME technology—using
mucin-covered microcosms—provided a detailed insight in the
long-term in vitro microbial colonisation of AIEC, an opportunistic
pathogen and abundant mucosal microbe. Moreover, it allowed to
evaluate the colonisation of a simulated mucus layer in the
presence of a resident mucosal and luminal intestinal microbiota.
It has to be considered that in this type of studies, the relevance of
the data in terms of potential interindividual variability (i.e.,
different effect of the test products due to a different composition
of the gut microbiota) may be questionable. Our aim was to
present a technology platform that might be applied on other
disease-causing microbes such as food-borne pathogens and to
provide evidences on the potential of several pre- and probiotic
strategies to repress AIEC from the mucosal compartment. Here
we showed—with the microbiota from one donor—that such
repression may occur via different mechanisms including the
production of reuterin, undissociated lactic acid or adhesion
inhibition. The evaluation of the role of the microbiota from
different donors on these mechanisms can be an interesting
future line of research. We also showed that the incorporation of a
mucosal environment in dynamic gut models may be a powerful
tool to obtain a more realistic view on processes that drive the
gastrointestinal microbiome.
MATERIALS AND METHODS
Preparation of growth media and bacterial suspensions
Unless stated otherwise, chemicals were obtained from Sigma (Bornem,
Belgium). Cosucra (Warcoing, Belgium) provided FOS with a purity of 96%
and a degree of polymerisation (DP) between 2 and 20 (Fibrulose F97) and
IN with a purity of 92% and a DP between 3 and 60 (Fibruline instant).
Friesland Campina Domo (Amersfoort, the Netherlands) provided GOS with
a purity of 98% and a DP between 3 and 8 (Vivinal GOS, Friesland Campina
Domo). BioActor (Maastricht, the Netherlands) provided water-extractable
LC-AX with a purity of 60%, a degree of substitution of 0.7 and an average
DP⩾ 60.
Ampicillin/erythromycin-resistant AIEC LF82, isolated from a chronic ileal
lesion of a CD patient, was used as the AIEC reference strain.21 Following
strains were used during this study: L. rhamnosus GG (LMG 18243), L. reuteri
1063 (ATCC 53608), L. acidophilus NCFM (Danisco, Brugge, Belgium),
L. mucosae LB219 and P. acidilactici LB1.19 Pure cultures of Lactobacillus sp.
were grown overnight in MRS medium (Oxoid, Cambridge, UK), while AIEC
was grown in BHI medium (Oxoid), both at 37 °C under aerobic conditions.
The nutritional medium of the M-SHIME consisted of (in g/l)
arabinogalactan (1.0), pectin (2.0), xylan (1.0), starch (3.0), glucose (0.4),
yeast extract (3.0), peptone (1.0), mucin (4.0) and cystein (0.5). Glycerol (1.0)
was added to enable L. reuteri among others to produce reuterin, a
bacteriocin.35 Pancreatic juice contained (in g/l) NaHCO3 (12.5), bile salts
(6.0) (Difco, Bierbeek, Belgium) and pancreatin (0.9).
Table 3. The average levels and s.d. of possible antimicrobial factors on time points after AIEC administration during the long-term M-SHIME
experiment (day 22–31): D- and L-lactic acid (mM), markers for reuterin production (3-HPA (mM) and 1,3-PDO (mM)) and the amount of biﬁdobacteria
and lactobacilli (log10 c.f.u. per ml), both in lumen and mucus
L-Control M-Control M-L. reuteri 1063 M-LC-AX M-IN
Antimicrobial factors:
D-lactic acid (mM) 1.24± 0.17a 1.61± 0.28ab 1.86± 0.21b 0.81± 0.13c 0.67± 0.15c
L-lactic acid (mM) 1.03± 0.18a 1.23± 0.30ab 1.37± 0.24b 0.72± 0.06c 0.59± 0.10c
3-HPA (mM) BDL BDL BDL BDL BDL
1,3-PDO (mM) 0.25± 0.15a 0.44± 0.46a 5.63± 5.68b 3.38±1.95b 3.11± 0.96b
Potential antimicrobial factors
Lactobacilli (log10 c.f.u. per ml)
Lumen 3.76± 1.27a 4.41± 0.74a 6.80± 0.17b 7.16±0.44b 6.91± 0.33b
Mucus — 3.51± 1.43a 5.41± 0.41b 6.94±0.35b 6.62± 0.86b
Biﬁdobacteria (log10 c.f.u. per ml)
Lumen 6.86± 0.24 6.31± 0.63 7.05± 0.46 6.94± 0.76 7.38± 0.68
Mucus — 6.03± 0.83a 6.43± 0.49b 7.59±0.83b 7.56± 0.63b
Abbreviations: AIEC, adherent-invasive Escherichia coli; BDL, below detection limit; IN, inulin; LC-AX, long-chain arabinoxylans.
For optimal visualisation, values that indicate antimicrobial effects against AIEC are in bold, while different superscripts indicate signiﬁcant differences
(a, b or c).
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Short-term AIEC mucin-adhesion assay
In a ﬁrst experiment, the intrinsic adhesion capacity of AIEC and the
Lactobacillus strains to mucins was determined. Moreover, inhibition of
AIEC adhesion by these (potential) probiotics and prebiotics (FOS, IN, GOS
and LC-AX) was evaluated. The mucin-adhesion assay was performed as
described previously.16 Brieﬂy, an overnight culture was diluted in fresh
growth medium (1:10) and allowed to grow for another 3 h. Bacterial cells
were washed three times with ﬁlter-sterilised 0.1 M phosphate-buffered
saline (PBS) at pH 5.9 and diluted to a ﬁnal density of ~ 108 cells per ml
(using ﬂow cytometry on live–dead staining). Immediately thereafter, 1 ml
of bacterial suspension and 1 ml of PBS were added to 12-well plates
covered with 1.2 ml mucin agar. Mucin agar was prepared by boiling
distilled H2O containing 5% gastric porcine mucin type II (Sigma) and 1%
agar. The pH was adjusted to 6.8 with 10 M NaOH (~350 μl per 100 ml).
Bacteria were allowed to adhere to this mucin layer under anaerobic
conditions, at 37 °C and under slight agitation (30 r.p.m.). After 80-min
incubation, non-adhered bacteria were removed, each well was washed
three times with PBS and the remaining adhered bacteria were detached
using 0.5% Triton X-100 in PBS. The total amount of initially added and
ﬁnally adhered bacteria was quantiﬁed using ﬂow cytometry. To evaluate
the inhibitory effect of a pro- or prebiotic on adhesion of AIEC, the extra
1 ml of PBS was supplemented with 108 probiotic cells per ml or 15 g/l of
the prebiotic compound. When co-cultured, the initially added and ﬁnally
adhered amounts of AIEC were determined using plate counts.
Short-term AIEC survival and growth inhibition assay
In a second experiment, the inhibitory effect of the selected pro- and
prebiotics on the survival/growth of AIEC in nutritional medium (initial
pH= 6.0) was evaluated during batch incubations. To do this, 15 ml
nutritional medium was added to penicillin bottles in which anaerobic
conditions were obtained ﬂushing with N2 during 15 cycles of 2 min each
at 800 mbar over-pressure and 900 mbar under-pressure. To test the
inhibitory effect of the probiotics, 5 × 106 cells per ml of both the probiotic
and AIEC were added. To test the inhibitory effect of prebiotics, 10 g/l
prebiotic (control—starch) was added to SHIME nutritional medium
containing 5× 106 cells per ml of both AIEC and additionally a mixed
microbiota from the ascending colon of the SHIME (~10 μl colon
suspension). This mixed microbiota was only added during the assays
with prebiotics as prebiotic compounds rather inhibit growth of AIEC
indirectly through stimulation of other microbes. Penicillin bottles were
incubated at 37 °C and 140 r.p.m. for 24 h. At the ﬁnal time point, pH,
D/L-lactic acid, reuterin, 1,3-PDO, SCFA, NH4 and counts of AIEC and the
probiotic were determined (c.f.u. per ml).
Dynamic gut model (M-SHIME)
Recently, we developed an in vitro model for the human intestinal tract
which accounts for both luminal and mucosal microbes, i.e., the M-SHIME,
based on the validated Simulator of the Human Intestinal Microbial
Ecosystem (SHIME, Ghent University-ProDigest, Belgium).19 The conven-
tional setup comprises ﬁve vessels, simulating the stomach, small intestine
and three colon regions. In this experiment, only the ascending colon was
simulated as this is the most relevant region regarding colonisation of AIEC
which is known to predominantly colonise the distal ileum and proximal
colon (Figure 3). The mucosal environment in the colon compartments
(500 ml) consisted of 80 mucin agar-covered microcosms (AnoxKaldnes K1
carrier, AnoxKaldnes AB, Lund, Sweden). Every 48 h, 50% of the mucin
N2
Stomach
Headspace connections
SHIME feed
Pancreatic juice
Liquid connection
Pump
(1) Control
pH controller
Acid/base
1. Conventional ascending colon
= “L-SHIME” (only luminal microbes)
2. Addition of mucin-covered 
microcosms to ascending colon
= “M-SHIME” (mucosal and luminal 
microbes)
(2a) Control (2b) Lactobacillus
reuteri
(2c) LC-AX (2d) IN
Coated with mucin
type II-agar
Small intestine
5 ascending
colon vessels:
Figure 3. The experimental design was based on the Simulator of the Human Intestinal Microbial Ecosystem (SHIME), a dynamic in vitro model
of the human gastrointestinal tract. In this experiment, only the ﬁrst colon compartment (ascending colon) was used and ﬁve compartments
were run in parallel. The ﬁrst unit consisted of a conventional setup that only contains luminal microbes (= luminal SHIME or L-SHIME (1)),
whereas the other four units were modiﬁed by incorporating a mucosal compartment (=mucosal SHIME or M-SHIME (2a) (2b) (2c) (2d)), which
contained 20 mucin-covered microcosms per 100 ml suspension. The three last units were treated with L. reuteri 1063, LC-AX and IN,
respectively.
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agar-covered microcosms has been replaced by fresh microcosms. The lid
of each reactor is slightly opened under constant nitrogen ﬂush and a net
containing 40 of the 80 microcosms is quickly replaced by a new one. Old
microcosms are then stored for further analysis. The colon regions were
simultaneously inoculated with 40 ml of faecal slurry derived from fresh
stools of a healthy human volunteer (26 years). Faecal samples were 1:5
(w/v) diluted in phosphate buffer (0.05 M, pH= 7) containing 1 g/l sodium
thioglycolate, followed by homogenisation with a Stomacher Lab-Blender
(Seward Medical, London, UK) and centrifugation to remove particulate
material (500 g, 1 min). By imposing identical conditions, similar microbial
composition and activity was achieved in the ﬁve parallel ascending colon
vessels.36 Three times per day, 140 ml nutritional medium and 60 ml
pancreatic juice were added to the stomach and small intestine,
respectively.
Experimental design M-SHIME study
Based on initial screenings, three treatments were applied in a third
experiment, a long-term M-SHIME study with ﬁve colon vessels, organised
as follows (Figure 3). The ﬁrst unit consisted of a conventional setup that
only simulates luminal microbes ( = L-SHIME), while the second also
simulates mucosal microbes ( =M-SHIME). These two units allowed
evaluating the importance of a mucosal environment for the colonisation
of AIEC. The M-SHIME unit also served as a control to the other three units
that also contained a mucosal environment ( =M-SHIME) but that were
treated with L. reuteri 1063, LC-AX and IN. After inoculation, human faecal
microbes were stabilised during 14 days, after which the treatment started.
For LC-AX and IN, 3 g per day was added, while for L. reuteri 1063 10 ml of
an overnight-grown culture, washed in PBS, was applied. On day 22, 23, 24
and 25, 10 ml of an overnight-grown culture of AIEC, washed in PBS, was
inoculated. The experiment was stopped at day 31. On the days that the
mucosal environment was renewed (day 22, 24, 27, 29 and 31), AIEC was
enumerated in the luminal and mucosal microbiota by means of plating.
Microbial community analysis: plate counts, ﬂow cytometry and
DGGE
AIEC numbers were determined by plating on a speciﬁc agar, i.e.,
MacConkey (Oxoid) supplemented with 50 mg/l ampicillin and 20 mg/l
erythromycin. Samples were serially diluted in saline solution (8.5 g/l NaCl),
after which plates were inoculated and incubated aerobically at 37 °C. Pure
cultures of AIEC and probiotic bacteria were quantiﬁed using ﬂow
cytometry after live–dead staining as described earlier.19
DNA extraction according to Boon et al.37 was performed on the pellet
of 1 ml suspension for luminal samples or 0.5 g mucin agar for mucosal
samples. Denaturing Gradient Gel Electrophoresis (DGGE) was applied to
separate PCR products of the 16S rRNA genes of Biﬁdobacterium sp. and
the total bacterial community. For the total community, general bacterial
primers 338F-GC and 518R were used,38 while the biﬁdobacteria required a
ﬁrst PCR using speciﬁc primers39 and a second PCR on the 1:100 diluted
PCR product using the general bacterial primers. Polyacrylamide gels (8%)
had a denaturing gradient ranging from 45 to 60% for the total microbiota
and from 50 to 65% for the biﬁdobacteria. Gels were run using an Ingeny
PhorU apparatus (Ingeny International, Goes, the Netherlands). Normal-
isation and further analysis was carried out using the BioNumerics software
version 5.10 (Applied Maths, Sint-Martens-Latem, Belgium). Speciﬁc bands
were cut and sequenced by ITT Biotech-Bioservice (Bielefeld, Germany).
Sequence data have been submitted to the EMBL database (accession
numbers HE985181–HE985183).
Metabolic activity analysis: lactic acid, SCFA, 3-HPA, NH4
+, 3-HPA
and 1,3-PDO
Lactic acid was measured using a D/L-lactic acid kit (R-Biopharm,
Mannheim, Germany), according to the manufacturer’s protocols. pH was
measured and used to calculate undissociated lactic acid as this is the
antimicrobial lactic acid fraction: undissociated lactic acid (%) = 1/[1+10^
(pH−pKa)] × 100%. Further, 3-HPA and 1,3-PDO were quantiﬁed by means
of HPLC to indicate the reuterin production, and SCFA by means of GC as
reported by De Weirdt et al.40 Using a Kjeltec Auto Distillation (FOSS
Benelux, Amersfoort, the Netherlands), NH4
+ in the sample was liberated as
NH3 by the addition of MgO. Released NH3 was distilled from the sample
into a boric acid solution, which was back-titrated using a 665 Dosimat
(Metrohm, Berchem, Belgium) and 686 Titroprocessor (Metrohm).
Statistics
All data were analysed using the SPSS 16 software (SPSS, Chicago, IL, USA).
Before investigating probability of intergroup differences, normality was
studied with a Kolmogorov–Smirnov test. Normal distributed data were
further analysed in a one-way ANOVA test, followed by post hoc Bonferroni
(equal variances) or Dunnett’s T3 (non-equal variances) analysis.
Non-normal distributed data were tested for differences using a
Kruskal–Wallis with Mann–Whitney test. Differences were considered
signiﬁcant when Po0.05.
ACKNOWLEDGEMENTS
M.M. and P.V.d.A. are Postdoctoral Fellows, supported by FWO-Vlaanderen (Research
Foundation of Flanders, Belgium). R.D.W. is a postdoctoral fellow supported by a
Concerted Research Action of the Flemish Community (GOA) (BOF12/GOA/008).
Finally, this work was partially supported by an SBO project (100016) from the
Agency for Innovation by Science and Technology (IWT).
CONTRIBUTIONS
P.V.d.A., M.D., R.D.W. and V.J. contributed to the experimental part, while P.V.d.A.,
M.M., S.P. and T.V.d.W. designed the experiments and wrote this manuscript.
COMPETING INTERESTS
The authors declare no conﬂict of interest.
REFERENCES
1. Zoetendal, E. G. et al. Mucosa-associated bacteria in the human gastrointestinal
tract are uniformly distributed along the colon and differ from the community
recovered from feces. Appl. Environ. Microbiol. 68, 3401–3407 (2002).
2. Van den Abbeele, P., Van de Wiele, T., Verstraete, W. & Possemiers, S. The host
selects mucosal and luminal associations of co-evolved gut microbes: a novel
concept. FEMS Microbiol. Rev. 35, 681–704 (2011).
3. Meyer-Hoffert, U. et al. Secreted enteric antimicrobial activity localises to the
mucus surface layer. Gut 57, 764–771 (2008).
4. Roos, S. & Jonsson, H. A high-molecular-mass cell-surface protein from
Lactobacillus reuteri 1063 adheres to mucus components. Microbiology 148,
433–442 (2002).
5. Koropatkin, N. M., Cameron, E. A. & Martens, E. C. How glycan metabolism shapes
the human gut microbiota. Nat. Rev. Microbiol. 10, 323–335 (2012).
6. Collado, M. C. et al. Antimicrobial peptides are among the antagonistic
metabolites produced by Biﬁdobacterium against Helicobacter pylori. Int. J.
Antimicrob. Agents 25, 385–391 (2005).
7. Salminen, S. et al. Functional food science and gastrointestinal physiology and
function. Br. J. Nutr. 80, S147–S171 (1998).
8. Gibson, G. R. & Roberfroid, M. B. Dietary modulation of the human colonic
microbiota—introducing the concept of prebiotics. J. Nutr. 125, 1401–1412
(1995).
9. Hooper, L. V., Xu, J., Falk, P. G., Midtvedt, T. & Gordon, J. I. A molecular sensor that
allows a gut commensal to control its nutrient foundation in a competitive
ecosystem. Proc. Natl Acad. Sci. USA 96, 9833–9838 (1999).
10. Bernet, M. F., Brassart, D., Neeser, J. R. & Servin, A. L. Lactobacillus-acidophilus
LA-1 binds to cultured human intestinal-cell lines and inhibits cell attachment
and cell invasion by enterovirulent bacteria. Gut 35, 483–489 (1994).
11. Willing, B. et al. Twin studies reveal speciﬁc imbalances in the mucosa-associated
microbiota of patients with ileal Crohn's disease. Inﬂamm. Bowel Dis. 15,
653–660 (2009).
12. Willing, B. P. et al. A Pyrosequencing study in twins shows that gastrointestinal
microbial proﬁles vary with inﬂammatory bowel disease phenotypes.
Gastroenterology 139, 1844–1854.e1841 (2010).
13. Darfeuille-Michaud, A. et al. High prevalence of adherent-invasive Escherichia coli
associated with ileal mucosa in Crohn's disease. Gastroenterology 127,
412–421 (2004).
14. Gibold, L. et al. The Vat-AIEC protease promotes crossing of the intestinal mucus
layer by Crohn's disease-associated Escherichia coli. Cell. Microbiol. 18,
617–631 (2016).
15. Ouwehand, A. C., Kirjavainen, P. V., Gronlund, M. M., Isolauri, E. & Salminen, S. J.
Adhesion of probiotic micro-organisms to intestinal mucus. Int. Dairy J. 9,
623–630 (1999).
Pro- and prebiotics repress AIEC from mucus
P Van den Abbeele et al
7
Published in partnership with Nanyang Technological University npj Bioﬁlms and Microbiomes (2016) 16016
16. Van den Abbeele, P. et al. In vitro model to study the modulation of the
mucin-adhered bacterial community. Appl. Microbiol. Biotechnol. 83, 349–359
(2009).
17. Tsilingiri, K. et al. Probiotic and postbiotic activity in health and disease: comparison
on a novel polarised ex-vivo organ culture model. Gut 61, 1007–1015 (2012).
18. Laparra, J. M. & Sanz, Y. Comparison of in vitro models to study bacterial adhesion
to the intestinal epithelium. Lett. Appl. Microbiol. 49, 695–701 (2009).
19. Van den Abbeele, P. et al. Incorporation of a mucosal environment in a dynamic
gut model results in a more representative colonization by lactobacilli. Microb.
Biotechnol. 5, 106–115 (2011).
20. Van den Abbeele, P. et al. Butyrate-producing Clostridium cluster XIVa species
speciﬁcally colonize mucins in an in vitro gut model. ISME J. 7, 949–961 (2013).
21. Darfeuille-Michaud, A. et al. Presence of adherent Escherichia coli strains in ileal
mucosa of patients with Crohn's disease. Gastroenterology 115, 1405–1413
(1998).
22. Van den Abbeele, P. et al. Arabinoxylans and inulin differentially modulate the
mucosal and luminal gut microbiota and mucin-degradation in humanized rats.
Environ. Microbiol. 13, 2667–2680 (2011).
23. Kankainen, M. et al. Comparative genomic analysis of Lactobacillus rhamnosus
GG reveals pili containing a human- mucus binding protein. Proc. Natl Acad. Sci.
USA 106, 17193–17198 (2009).
24. Barnich, N., Boudeau, J., Claret, L. & Darfeuille-Michaud, A. Regulatory and
functional co-operation of ﬂagella and type 1 pili in adhesive and invasive
abilities of AIEC strain LF82 isolated from a patient with Crohn's disease. Mol.
Microbiol. 48, 781–794 (2003).
25. Martinez-Medina, M. et al. Molecular diversity of Escherichia coli in the human
gut: New ecological evidence supporting the role of adherent-invasive E. coli
(AIEC) in Crohn's disease. Inﬂamm. Bowel Dis. 15, 872–882 (2009).
26. Lee, H. Y. et al. Prophylactic uses of probiotics as a potential alternative to
antimicrobials in food animals. Food Sci. Biotechnol. 17, 191–194 (2008).
27. Khedkar, J. N., Dave, J. M. & Sannabhadti, S. S. Antibacterial activity
associated with Biﬁdobacterium adolescentis. J. Food Sci. Technol. 35,
527–529 (1998).
28. Stöber, H., Maier, E. & Schmidt, H. Protective effects of Lactobacilli, Biﬁdobacteria
and Staphylococci on the infection of cultured HT29 cells with different
enterohemorrhagic Escherichia coli serotypes are strain-speciﬁc. Int. J. Food
Microbiol. 144, 133–140 (2010).
29. Axelsson, L. T., Chung, T. C., Dobrogosz, W. J. & Lindgren, S. E. Production of a
broad spectrum antimicrobial substance by Lactobacillus reuteri. Microb. Ecol.
Health Dis. 2, 131–136 (1989).
30. Talarico, T. L., Casas, I. A., Chung, T. C. & Dobrogosz, W. J. Production and isolation
of reuterin, a growth inhibitor produced by Lactobacillus reuteri. Antimicrob.
Agents Chemother. 32, 1854–1858 (1988).
31. Cleusix, V., Lacroix, C., Vollenweider, S., Duboux, M. & Le Blay, G. Inhibitory activity
spectrum of reuterin produced by Lactobacillus reuteri against intestinal bacteria.
BMC Microbiol. 7, 101 (2007).
32. Cleusix, V., Lacroix, C., Vollenweider, S. & Le Blay, G. Glycerol induces reuterin
production and decreases Escherichia coli population in an in vitro model of
colonic fermentation with immobilized human feces. FEMS Microbiol. Ecol. 63,
56–64 (2008).
33. Marchesi, J. R. et al. Rapid and noninvasive metabonomic characterization of
inﬂammatory bowel disease. J. Proteome Res. 6, 546–551 (2007).
34. Gibson, G. R., McCartney, A. L. & Rastall, R. A. Prebiotics and resistance to
gastrointestinal infections. Br. J. Nutr. 93 Suppl 1, S31–S34 (2005).
35. Vollenweider, S. & Lacroix, C. 3-Hydroxypropionaldehyde: applications and
perspectives of biotechnological production. Appl. Microbiol. Biotechnol. 64,
16–27 (2004).
36. Van den Abbeele, P. et al. Microbial community development in a dynamic gut
model is reproducible, colon-region speciﬁc and selects for Bacteroidetes and
Clostridium cluster IX. Appl. Environ. Microbiol. 76, 5237–5246 (2010).
37. Boon, N., Top, E. M., Verstraete, W. & Siciliano, S. D. Bioaugmentation as a tool to
protect the structure and function of an activated-sludge microbial community
against a 3-chloroaniline shock load. Appl. Environ. Microbiol. 69, 1511–1520
(2003).
38. Muyzer, G., Dewaal, E. C. & Uitterlinden, A. G. Proﬁling of complex microbial-
populations by denaturing gradient gel-electrophoresis of polymerase chain
reaction-ampliﬁed genes-coding for 16S ribosomal-RNA. Appl. Environ. Microbiol.
59, 695–700 (1993).
39. Satokari, R. M., Vaughan, E. E., Akkermans, A. D. L., Saarela, M. & de Vos, W. M.
Biﬁdobacterial Diversity in Human Feces Detected by Genus-Speciﬁc PCR and
Denaturing Gradient Gel Electrophoresis. Appl. Environ. Microbiol. 67, 504–513
(2001).
40. De Weirdt, R. et al. Human faecal microbiota display variable patterns of glycerol
metabolism. FEMS Microbiol. Ecol. 74, 601–611 (2010).
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative Commons
license, users will need to obtain permission from the license holder to reproduce the
material. To view a copy of this license, visit http://creativecommons.org/licenses/
by/4.0/
© The Author(s) 2016
Supplementary Information accompanies the paper on the npj Bioﬁlms and Microbiomes website (http://www.nature.com/npjbioﬁlms)
Pro- and prebiotics repress AIEC from mucus
P Van den Abbeele et al
8
npj Bioﬁlms and Microbiomes (2016) 16016 Published in partnership with Nanyang Technological University
